<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04829903</url>
  </required_header>
  <id_info>
    <org_study_id>DULACAI37628</org_study_id>
    <nct_id>NCT04829903</nct_id>
  </id_info>
  <brief_title>Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin</brief_title>
  <official_title>Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin: Results From a Randomized Double Blinded Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corporacion Parc Tauli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corporacion Parc Tauli</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy and effect on glycemic control of Dulaglutide versus Liraglutide in&#xD;
      obese Type 2 diabetic adolescents using metformin&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To observe the efficacy, effect on glycemic control, impact on BMI and incidence of adverse&#xD;
      effects of Dulaglutide and to compare it to Liraglutide in individuals aged thirteen to&#xD;
      eighteen who have Type 2 diabetes mellitus and are obese.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2, 2020</start_date>
  <completion_date type="Anticipated">November 20, 2021</completion_date>
  <primary_completion_date type="Actual">March 29, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic level</measure>
    <time_frame>24 weeks for the duration of the study</time_frame>
    <description>HbA1c</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BMI</measure>
    <time_frame>24 weeks for the duration of the study</time_frame>
    <description>BMI measurements using weight and height measurements (anthropometric)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>24 weeks for the duration of the study</time_frame>
    <description>Recording of adverse effects</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Type 2 Diabetes Treated With Insulin</condition>
  <condition>Obesity</condition>
  <condition>Adolescent Obesity</condition>
  <arm_group>
    <arm_group_label>Group DUL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group taking Dulaglutide injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group LIR</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group taking Liraglutide injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dulaglutide</intervention_name>
    <description>Dulaglutide injections</description>
    <arm_group_label>Group DUL</arm_group_label>
    <other_name>Group DUL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Liraglutide injections</description>
    <arm_group_label>Group LIR</arm_group_label>
    <other_name>Group LIR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 Diabetes Mellitus&#xD;
&#xD;
          -  Obese&#xD;
&#xD;
          -  Taking metformin&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non obese&#xD;
&#xD;
          -  Not taking metformin&#xD;
&#xD;
          -  Taking other injectable diabetic medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadia Hussain, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Al Ain University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zainab Khan</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Corporacion Parc Tauli</investigator_affiliation>
    <investigator_full_name>Dr Zainab Khan</investigator_full_name>
    <investigator_title>Chief Resident</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Pediatric Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Dulaglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

